Effect of folylpolyglutamate synthase A22G polymorphism on the risk and survival of patients with acute lymphoblastic leukemia
- Authors:
- Published online on: May 26, 2014 https://doi.org/10.3892/ol.2014.2175
- Pages: 731-735
Metrics: Total
Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
Abstract
Folylpolyglutamate synthase (FPGS) is the key enzyme that converts the chemotherapeutic agent, methotrexate (MTX), into MTX polyglutamate. An A22G polymorphism has been found in the FPGS gene. This study aimed to evaluated whether the A22G polymorphism in the FPGS gene is associated with an increased risk of acute lymphoblastic leukemia (ALL) and whether it plays a role in increasing the survival of patients with ALL. In this study, a total of 70 patients with ALL and 100 healthy individuals were genotyped by polymerase chain reaction and sequencing methods. The homozygous variant, 22G/G [odds ratio (OR)=3.88; 95% confidence interval (CI): 2.50‑6.03] and the heterozygous variant, 22A̸G (OR=1.37; 95% CI: 1.26‑48.95) were risk factors for ALL. Patients with the 22A̸G genotype had an OR of 1.81 (95% CI: 1.57‑5.74; P=0.049) and carriers of the 22G̸G genotype had an OR of 2.44 (95% CI: 2.40‑11.82; P=0.017) for relapse. A significant association between the A22G polymorphism and survival of patients with ALL was found (P<0.05); whereas, individuals with A̸G or G̸G genotypes had a decreased overall survival (log‑rank test, P=0.044). Although preliminary, these data suggest that the genotypes of the A22G polymorphism may be risk factors for ALL and may play a role in the survival of patients with ALL.
